Blood pressure reduction: an added benefit of sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes.
作者信息
Majewski Colleen, Bakris George L
机构信息
American Society of Hypertension Comprehensive Hypertension Center, Section of Endocrinology, Diabetes, and Metabolism, Department of Medicine, University of Chicago Medicine, Chicago, IL.
American Society of Hypertension Comprehensive Hypertension Center, Section of Endocrinology, Diabetes, and Metabolism, Department of Medicine, University of Chicago Medicine, Chicago, IL
出版信息
Diabetes Care. 2015 Mar;38(3):429-30. doi: 10.2337/dc14-1596.
Abstract
摘要
相似文献
1
Blood pressure reduction: an added benefit of sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes.血压降低：2型糖尿病患者使用钠-葡萄糖协同转运蛋白2抑制剂的额外益处。
Diabetes Care. 2015 Mar;38(3):429-30. doi: 10.2337/dc14-1596.
2
Blood pressure effects of SGLT2 inhibitors make them an attractive option in diabetic patients with hypertension.钠-葡萄糖协同转运蛋白2（SGLT2）抑制剂对血压的影响使其成为糖尿病合并高血压患者的一个有吸引力的选择。
J Am Soc Hypertens. 2016 Mar;10(3):186-7. doi: 10.1016/j.jash.2016.01.001.
3
Effect of Sodium-Glucose Cotransport-2 Inhibitors on Blood Pressure in People With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of 43 Randomized Control Trials With 22 528 Patients.钠-葡萄糖协同转运蛋白2抑制剂对2型糖尿病患者血压的影响：对43项随机对照试验（涉及22528例患者）的系统评价和荟萃分析
J Am Heart Assoc. 2017 May 25;6(6):e004007. doi: 10.1161/JAHA.116.004007.
4
Sodium-glucose cotransporter 2 inhibitors: the new option for diabetes mellitus management.钠-葡萄糖协同转运蛋白2抑制剂：糖尿病管理的新选择。
South Med J. 2015 Feb;108(2):82-90. doi: 10.14423/SMJ.0000000000000233.
5
SGLT2 inhibitors for diabetes: turning symptoms into therapy.用于治疗糖尿病的钠-葡萄糖协同转运蛋白2抑制剂：变症状为疗法。
Lancet. 2013 Sep 14;382(9896):917-8. doi: 10.1016/S0140-6736(13)60902-2. Epub 2013 Jul 12.
6
Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease.卡格列净治疗2型糖尿病合并慢性肾脏病患者52周的疗效与安全性
Diabetes Obes Metab. 2014 Oct;16(10):1016-27. doi: 10.1111/dom.12348. Epub 2014 Jul 22.
7
Glucagon-like peptide-1 receptor agonists and sodium-glucose co-transporter-2 inhibitors: Sequential or simultaneous start?胰高血糖素样肽-1受体激动剂与钠-葡萄糖协同转运蛋白2抑制剂：序贯起始还是同时起始？
Diabetes Obes Metab. 2017 Jun;19(6):909-911. doi: 10.1111/dom.12897. Epub 2017 Mar 8.
8
Canagliflozin - something new for type 2 diabetes, but is it safe and efficacious?卡格列净——2型糖尿病的新药物，但它安全有效吗？
Expert Opin Pharmacother. 2014 Feb;15(3):437-41. doi: 10.1517/14656566.2014.868885. Epub 2013 Dec 31.
9
Glyxambi--a new combination for type 2 diabetes.格列净二甲双胍片——2型糖尿病的新型复方制剂
Med Lett Drugs Ther. 2015 Apr 27;57(1467):65-6.
10
Empagliflozin for the treatment of Type 2 diabetes.恩格列净治疗 2 型糖尿病。
Expert Rev Clin Pharmacol. 2014 May;7(3):271-9. doi: 10.1586/17512433.2014.908703. Epub 2014 Apr 9.
引用本文的文献
1
Sodium-glucose co-transporter 2 inhibitor-induced increase in adenosine promotes lipolysis and weight reduction by activating reno-adipose autonomic neurocircuitry.钠-葡萄糖协同转运蛋白2抑制剂诱导的腺苷增加通过激活肾-脂肪自主神经回路促进脂肪分解和体重减轻。
Hypertens Res. 2025 Jul 23. doi: 10.1038/s41440-025-02287-9.
2
Sodium-Glucose Transporter-2 Inhibitors (SGLT2i) and Myocardial Ischemia: Another Compelling Reason to Consider These Agents Regardless of Diabetes.钠-葡萄糖协同转运蛋白2抑制剂（SGLT2i）与心肌缺血：无论是否患有糖尿病，都有另一个令人信服的理由考虑使用这些药物。
Int J Mol Sci. 2025 Feb 27;26(5):2103. doi: 10.3390/ijms26052103.
3
Effects of a New Group of Antidiabetic Drugs in Metabolic Diseases.新型抗糖尿病药物对代谢性疾病的影响。
Rev Cardiovasc Med. 2023 Feb 2;24(2):36. doi: 10.31083/j.rcm2402036. eCollection 2023 Feb.
4
Effect of SGLT2 inhibitors on kidney function of type 2 diabetes patients during Ramadan: A systematic review.斋月期间SGLT2抑制剂对2型糖尿病患者肾功能的影响：一项系统评价
Qatar Med J. 2024 Jun 20;2024(3):26. doi: 10.5339/qmj.2024.26. eCollection 2024.
5
Diabetes and Stroke: Impact of Novel Therapies for the Treatment of Type 2 Diabetes Mellitus.糖尿病与中风：2型糖尿病新型治疗方法的影响
Biomedicines. 2024 May 16;12(5):1102. doi: 10.3390/biomedicines12051102.
6
Blood Pressure Effects of SGLT2 Inhibitors: Mechanisms and Clinical Evidence in Different Populations.SGLT2 抑制剂对血压的影响：不同人群的作用机制和临床证据。
Curr Hypertens Rep. 2023 Dec;25(12):429-435. doi: 10.1007/s11906-023-01281-1. Epub 2023 Nov 10.
7
The Impact of SGLT2 Inhibitors in the Heart and Kidneys Regardless of Diabetes Status.SGLT2 抑制剂对心脏和肾脏的影响，无论是否存在糖尿病。
Int J Mol Sci. 2023 Sep 18;24(18):14243. doi: 10.3390/ijms241814243.
8
Overall Efficacy and Safety of Sodium-Glucose Cotransporter 2 Inhibitor Luseogliflozin Versus Dipeptidyl-Peptidase 4 Inhibitors: Multicenter, Open-Label, Randomized-Controlled Trial (J-SELECT study).钠-葡萄糖协同转运蛋白2抑制剂鲁格列净与二肽基肽酶4抑制剂的总体疗效和安全性：多中心、开放标签、随机对照试验（J-SELECT研究）
Diabetes Ther. 2023 Sep;14(9):1517-1535. doi: 10.1007/s13300-023-01438-w. Epub 2023 Jul 6.
9
Contemporary trends in the utilization of second-line pharmacological therapies for type 2 diabetes in the United States and the United Kingdom.当代美国和英国 2 型糖尿病二线药物治疗的利用趋势。
Diabetes Obes Metab. 2023 Oct;25(10):2980-2988. doi: 10.1111/dom.15196. Epub 2023 Jul 3.
10
The Role of Sodium-Glucose Cotransporter-2 Inhibitors in Heart Failure Management: The Continuing Challenge of Clinical Outcome Endpoints in Heart Failure Trials.钠-葡萄糖协同转运蛋白2抑制剂在心力衰竭管理中的作用：心力衰竭试验中临床结局终点面临的持续挑战。
Pharmaceutics. 2023 Mar 29;15(4):1092. doi: 10.3390/pharmaceutics15041092.
本文引用的文献
1
Dapagliflozin: a review of its use in patients with type 2 diabetes.达格列净：用于治疗 2 型糖尿病患者的综述。
Drugs. 2014 Dec;74(18):2191-209. doi: 10.1007/s40265-014-0324-3.
2
Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension.恩格列净可降低 2 型糖尿病合并高血压患者的血压。
Diabetes Care. 2015 Mar;38(3):420-8. doi: 10.2337/dc14-1096. Epub 2014 Sep 30.
3
Efficacy and safety of canagliflozin in patients with type 2 diabetes and stage 3 nephropathy.卡格列净在2型糖尿病合并3期肾病患者中的疗效和安全性。
Am J Nephrol. 2014;40(1):64-74. doi: 10.1159/000364909. Epub 2014 Jul 17.
4
Canagliflozin: a review of its use in patients with type 2 diabetes mellitus.卡格列净：用于 2 型糖尿病患者的评价。
Drugs. 2014 May;74(7):807-24. doi: 10.1007/s40265-014-0225-5.
5
Blood pressure effects of sodium-glucose co-transport 2 (SGLT2) inhibitors.钠-葡萄糖协同转运蛋白2（SGLT2）抑制剂对血压的影响。
J Am Soc Hypertens. 2014 May;8(5):330-9. doi: 10.1016/j.jash.2014.02.003. Epub 2014 Feb 12.
6
The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus.恩格列净对无并发症的1型糖尿病患者动脉僵硬度和心率变异性的影响。
Cardiovasc Diabetol. 2014 Jan 29;13:28. doi: 10.1186/1475-2840-13-28.
7
NICE hypertension guideline 2011: evidence based evolution.英国国家卫生与临床优化研究所2011年高血压指南：基于证据的演变
BMJ. 2012 Jan 13;344:e181. doi: 10.1136/bmj.e181.
Zotero 插件